AU1028601A - Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity - Google Patents
Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activityInfo
- Publication number
- AU1028601A AU1028601A AU10286/01A AU1028601A AU1028601A AU 1028601 A AU1028601 A AU 1028601A AU 10286/01 A AU10286/01 A AU 10286/01A AU 1028601 A AU1028601 A AU 1028601A AU 1028601 A AU1028601 A AU 1028601A
- Authority
- AU
- Australia
- Prior art keywords
- isoquinoline
- 5ht1b
- 5ht1a
- combined
- quinazoline derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title abstract 4
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 title 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9926304 | 1999-11-05 | ||
| GBGB9926304.8A GB9926304D0 (en) | 1999-11-05 | 1999-11-05 | Novel compounds |
| GB0017880A GB0017880D0 (en) | 2000-07-20 | 2000-07-20 | Novel compounds |
| GB0017880 | 2000-07-20 | ||
| PCT/EP2000/010908 WO2001032626A1 (en) | 1999-11-05 | 2000-11-02 | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1028601A true AU1028601A (en) | 2001-05-14 |
Family
ID=26244692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU10286/01A Abandoned AU1028601A (en) | 1999-11-05 | 2000-11-02 | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050239797A1 (enExample) |
| EP (1) | EP1228043B1 (enExample) |
| JP (1) | JP2003513075A (enExample) |
| AT (1) | ATE286883T1 (enExample) |
| AU (1) | AU1028601A (enExample) |
| DE (1) | DE60017446T2 (enExample) |
| ES (1) | ES2234683T3 (enExample) |
| PE (1) | PE20010956A1 (enExample) |
| UY (1) | UY26426A1 (enExample) |
| WO (1) | WO2001032626A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| DE10315569A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazolverbindungen |
| DE10315571A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Pyrazolverbindungen |
| DE10315573A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazole |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| RU2006129464A (ru) * | 2004-01-16 | 2008-02-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| US20090099175A1 (en) * | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| WO2008115593A1 (en) | 2007-03-21 | 2008-09-25 | The University Of Montana | 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents |
| US8987473B2 (en) | 2011-01-28 | 2015-03-24 | Sato Pharmaceutical Co., Ltd. | Ring-fused compound |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| KR101709127B1 (ko) * | 2015-06-16 | 2017-02-22 | 경동제약 주식회사 | Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법 |
| CN112480007B (zh) * | 2020-12-08 | 2022-11-18 | 宿迁市科莱博生物化学有限公司 | 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法 |
| WO2025190395A2 (en) * | 2024-03-14 | 2025-09-18 | Pharmaengine, Inc. | Mta-cooperative prmt5 inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778440A (en) * | 1970-12-07 | 1973-12-11 | Sandoz Ag | 1-substituted amino-isoquinolines and nitrates thereof |
| US3932412A (en) * | 1970-12-07 | 1976-01-13 | Sandoz, Inc. | 1-(4-Hydroxyalkylpiperazino)-isoquinoline nitrates |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| AU732863B2 (en) * | 1997-04-18 | 2001-05-03 | Smithkline Beecham Plc | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity |
| WO1998047868A1 (en) * | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
| WO1999018077A1 (en) * | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| JP2002508366A (ja) * | 1997-12-12 | 2002-03-19 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途 |
| WO2000006575A2 (en) * | 1998-07-28 | 2000-02-10 | Smithkline Beecham Plc | Azabicyclic compounds |
-
2000
- 2000-11-02 EP EP00971423A patent/EP1228043B1/en not_active Expired - Lifetime
- 2000-11-02 AT AT00971423T patent/ATE286883T1/de not_active IP Right Cessation
- 2000-11-02 JP JP2001534778A patent/JP2003513075A/ja active Pending
- 2000-11-02 AU AU10286/01A patent/AU1028601A/en not_active Abandoned
- 2000-11-02 DE DE60017446T patent/DE60017446T2/de not_active Expired - Fee Related
- 2000-11-02 WO PCT/EP2000/010908 patent/WO2001032626A1/en not_active Ceased
- 2000-11-02 ES ES00971423T patent/ES2234683T3/es not_active Expired - Lifetime
- 2000-11-03 PE PE2000001176A patent/PE20010956A1/es not_active Application Discontinuation
- 2000-11-03 UY UY26426A patent/UY26426A1/es not_active Application Discontinuation
-
2005
- 2005-06-13 US US11/151,008 patent/US20050239797A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2234683T3 (es) | 2005-07-01 |
| WO2001032626A1 (en) | 2001-05-10 |
| EP1228043B1 (en) | 2005-01-12 |
| PE20010956A1 (es) | 2001-09-15 |
| UY26426A1 (es) | 2001-05-31 |
| US20050239797A1 (en) | 2005-10-27 |
| EP1228043A1 (en) | 2002-08-07 |
| DE60017446T2 (de) | 2006-03-02 |
| JP2003513075A (ja) | 2003-04-08 |
| ATE286883T1 (de) | 2005-01-15 |
| DE60017446D1 (de) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL142768A0 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| WO2000035919A3 (en) | Quinoline derivatives | |
| AU3126600A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| AU2002220715A1 (en) | Indolsulfonyl compounds useful in the treatment of cns disorders | |
| MXPA02012712A (es) | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. | |
| WO1999002502A3 (en) | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation | |
| AU1028601A (en) | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity | |
| PL335484A1 (en) | Derivatives of heteroarylhexamide, their production and application as selective inhibitors of mip-1a being assimilated by its ccr1 receptor | |
| HUP0002031A3 (en) | Use of benzotiophen derivatives for production pharmaceutical compositions having activity against central nervous system disorders | |
| MY122771A (en) | Heterocyclically substituted benzimidazoles, their preparation and use thereof | |
| HUP0301834A3 (en) | Use of heterocyclic dihydropyrimidine derivatives for the preparation of pharmaceutical compositions with potassim channel activity, novel derivatives and pharmaceutical compositions containing them | |
| WO1999017755A3 (en) | Medicaments | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| WO2002072536A8 (en) | Urea derivatives having vanilloid receptor (vr1) antagonist activity | |
| MY132229A (en) | Indole derivatives as 5-ht receptor antagonist | |
| WO2001098268A3 (en) | Piperidine amides as modulators of chemokine receptor activity | |
| DE60203797D1 (de) | Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten | |
| CA2315227A1 (en) | Arylpiperazines having activity at the serotonin 1a receptor | |
| HUP0000288A3 (en) | Azetidinone derivatives as inhibitors of the enzymatic activity of psa, intermediates, process for their preparation and pharmaceutical compositions thereof | |
| AU2001266152A1 (en) | Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them | |
| WO1996023769A3 (en) | Heterocyclic compounds possessing 5ht2c receptor antagonist activity | |
| WO2001098270A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| WO2001098269A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| CA2370834A1 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| AP9801202A0 (en) | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase | ||
| TH | Corrigenda |
Free format text: IN VOL 15, NO 35, PAGE(S) 7527-7530 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 59963/00, 77978/00, 10286/01, 10391/01, 10423/01, 11276/01, 11598/01, 11600/01, 11605/01, 11619/01, 11643/01, 12747/01, 12868/01, 12870/01, 12873/01, 12880/01, 12882/01, 12920/01, 12922/01, 12943/01, 12963/01, 13933/01 AND 17215/01 |
|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |